Product logins

Find logins to all Clarivate products below.


Alopecia Areata | Treatment Algorithms: Claims Data Analysis | US | 2024

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids and topical or contact immunotherapy are commonly prescribed. Two JAK inhibitors—Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Litfulo (ritlecitinib)—are approved for severe AA. As the treatment landscape continues to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices in AA and to define the market niche for emerging products.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
  • How has Olumiant been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key drugs: Contact allergens, corticosteroids, cyclosporine A, finasteride, Litfulo, Jakafi, methotrexate, Olumiant, pimecrolimus, retinoids, tacrolimus (topical), Xeljanz

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…